id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-E-1091-0005,FDA,FDA-2021-E-1091,Determination of Regulatory Review Period for Purposes of Patent Extension; Pemazyre,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:47:16Z,2023-26996,0,0,0900006486316628